Clinical Trial Update: Imatinib Mesylate in Treating Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Imatinib Mesylate in patients with myelofibrosis has completed. The study also addresses related myeloproliferative neoplasms …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Myelomonocytic Leukemia
• Polycythemia Vera

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Myelomonocytic Leukemia, Essential Thrombocythemia | Phase 2 | Status: COMPLETED